You are here
Aura Appoints New Director
TORONTO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Aura Health Inc. (the “Company” or “Aura”) (CSE: BUZZ) wishes to announce the following changes to its board of directors (the “Board”). Effective immediately, Joel Freudman has been appointed to the Board as an independent director and Chair of the Board’s Audit Committee, subject to regulatory approval by the Canadian Securities Exchange. Mr. Freudman is the President of Resurgent Capital Corp., a Toronto-based merchant bank focused on undervalued micro-cap Canadian public companies. He is also President and CEO and a Director of Trius Investments Inc. (TSXV:TRU.H). Mr. Freudman started his career in private practice as a securities and M&A lawyer and subsequently transitioned to in-house legal counsel for various wealth management firms and major Canadian financial institutions. Mr. Freudman is a member of the Law Society of Ontario, holds a Juris Doctor degree from the University of Western Ontario and a Bachelor of Commerce degree from the University of Toronto.
In association with the appointment of Mr. Freudman, Jimmy Gravel has resigned from the Board in order to pursue other business opportunities, effective immediately. The Board would like to thank Mr. Gravel for his service to the Company and wishes him the best in his future endeavours.
Daniel Cohen, CEO of Aura, commented: “We are happy to add Joel to the Board for his corporate governance and transactional expertise, which will help as we accelerate our international growth strategy. At the same time, we also want to sincerely thank Jimmy Gravel for his contributions to the Company and wish him the best in his future endeavours.”
About Aura Health Inc.
Aura, through its wholly-owned Delaware subsidiary Green Global Properties Inc. (“Green Global”), owns a 30% interest in four medical marijuana clinics in Las Vegas, Nevada; Mesa, Arizona; Tucson, Arizona; and Hollywood, Florida. Green Global has an option to increase its interest in each such clinic (other than the Nevada clinic) to 51%.
Aura’s common shares trade on the Canadian Securities Exchange under the symbol “BUZZ”. For updates on the Company’s activities and to see its investor presentation, please visit Aura’s web site at www.aurahealthinc.com.
For further information, please contact:
Daniel Cohen, CEO - (647) 202-1824
David Posner, Director and Chairman - (647) 985-6727
Caution Regarding Forward-Looking Information:
This news release contains “forward-looking information” within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by words and phrases such as “plans”, “expects” “scheduled”, “estimates”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken or occur. Forward-looking information in this news release includes, without limitation, statements regarding the Company’s future expansion plans. This forward-looking information consists of disclosure regarding possible events, conditions or results, and is based on numerous assumptions, including that the new director appointment will be approved and that Aura will be able to successfully develop and execute its plans for international growth.
The forward-looking information in this news release is subject to numerous risks and uncertainties that may cause Aura’s actual results or performance to differ materially from those expressed or implied by such forward-looking information, including but not limited to: regulatory approval processes; challenges in business performance and execution; and other risks described in the Company’s continuous disclosure documents. Accordingly, investors should not place undue reliance on such forward-looking information. The Company does not undertake to update any forward-looking information herein, except as may be required by applicable securities laws.